Increasing interest in the development of Oligonucleotide therapeutics among Biotech and Large Pharma companies has been recently fuelled by the approval of Mipomersen. Sensitive and selective bioanalytical methodologies are key to the development process. Chromatographic and hybridization ELISA approaches will be reviewed, compared and contrasted.

An overview of oligonucleotide therapeutics in multiple clinical stages will be given. The available bioanalytical platforms for quantitation of oligonucleotide therapeutics will be discussed, with a focus on the hybridization ELISA assays.


  • Jonathan Reeves, PhD, Scientific Director, Immunochemistry, Charles River